Diltiazem, also known as (2S,3S)-3-acetoxy-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one hydrochlorid has a vasodilating activity attributed to the (2S,3S)-isomer. Diltiazem is a potent
vasodilator, increasing blood flow and variably decreasing the
heart rate via strong depression of
A-V node conduction. It binds to the alpha-1 subunit of L-type calcium channels in a fashion somewhat similar to
verapamil, another nondihydropyridine (non-DHP) calcium channel blocker. Chemically, it is based upon a
1,4-thiazepine ring, making it a
benzothiazepine-type calcium channel blocker. It is a potent and mild vasodilator of
coronary and
peripheral vessels, respectively, which reduces
peripheral resistance and
afterload, though not as potent as the
dihydropyridine (DHP) calcium channel blockers. This results in minimal reflexive
sympathetic changes. Diltiazem has negative
inotropic,
chronotropic, and
dromotropic effects. This means diltiazem causes a decrease in
heart muscle contractility – how strong the beat is, lowering of heart rate – due to slowing of the
sinoatrial node, and a slowing of conduction through the
atrioventricular node – increasing the time needed for each beat. Each of these effects results in reduced
oxygen consumption by the heart, reducing angina, typically
unstable angina, symptoms. These effects also reduce blood pressure by causing less blood to be pumped out. ==Research==